Crispr Therapeutics shares tumble after significant earnings miss
Thomas J. Shaw, President and CEO of Retractable Technologies Inc . (NYSE:RVP), reported a recent acquisition of company stock. The purchase comes as the company faces challenging conditions, with InvestingPro data showing a revenue decline of 24% in the last twelve months and negative profit margins. Shaw purchased 166 shares of common stock at a weighted average price of $0.693 per share, totaling approximately $115. Following this transaction, Shaw directly owns 15,201,278 shares. Additionally, Shaw indirectly holds 831,600 shares, with investment power over 500,000 shares as a trustee and voting control over the remainder through a voting agreement. This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on August 22, 2024. While the company maintains strong liquidity with a current ratio of 8.34, InvestingPro analysis reveals high stock volatility with a beta of 2.28, and the stock has declined 33% over the past year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.